| Autor: |
VAN DEN HOOGEN, F. H. J., SPRONK, P. E., BOERBOOMS, A. M. T., BOOTSMA, H., DE ROOIJ, D. J. R. A. M., KALLENBERG, C. G. M., VAN DE PUTTE, L. B. A. |
| Zdroj: |
British Journal of Rheumatology; 12/1/1994, Vol. 33 Issue 12, p1117-1120, 4p |
| Abstrakt: |
The records of 46 patients with anti-(Ul)snRNP antibodies and a minimal period of follow-up after first clinical presentation of at least 5 yr were examined with emphasis on symptoms contributing to established criteria of SLE, systemic sclerosis (SSc), RA or dermato- or polymyositis (DM/PM). At first clinical presentation 13 (28%) of the 46 patients studied fulfilled ARA-criteria for SLE ( = 10), RA ( = 2) and SSc ( = 1), and 33 (72%) were classified as mixed connective tissue disease (MCTD). During follow-up 18 patients initially classified as MCTD were now classified as SLE ( = 5), SSc ( = 7), RA ( =3), or a combination of these disorders ( = 3). A transformation of MCTD towards these connective tissue diseases occurred 2.6 ± 3 yr (mean ± S.D.) after first clinical presentation. At the end of the follow-up period 67% of the patients fulfilled ARA criteria for SLE, SSc, RA or a combination of these diseases. The majority of patients with anti-(Ul)snRNP antibodies have or will develop a classified connective tissue disease within 5 yr after clinical presentation. This undermines the concept of MCTD being a distinct clinical entity. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
